Cancer vaccines market seen doubling to $14.26B by 2033

By AI, Created 11:45 AM UTC, May 22, 2026, /AGP/ – Coherent Market Insights says the global cancer vaccines market is projected to rise from $7.46 billion in 2026 to $14.26 billion by 2033. The report breaks down growth drivers, regional trends, and competition across therapeutic, prophylactic and combined vaccine segments.

Why it matters: - The cancer vaccines market is projected to nearly double by 2033, signaling rising demand for immunotherapy and preventive oncology tools. - The forecast points to new opportunities for drugmakers, investors and oncology providers as the market expands across multiple cancer types and care settings.

What happened: - Coherent Market Insights published a market study on the global cancer vaccines market on May 22, 2026. - The report estimates market value at $7.46 billion in 2026 and $14.26 billion by 2033. - The study covers regional and global market trends from 2026 to 2033. - The report includes a sample copy request.

The details: - The report analyzes market size, production, revenue, consumption, CAGR, gross margin and pricing trends. - It uses primary and secondary research methods and includes market dynamics, pricing structures, production-consumption patterns, company profiles and cost analysis. - The player list includes BioVaxTech, ImmunoGenix, ProMedica Therapeutics, NeoVax Bio, CelluVax Inc., OncoVax Solutions, MedGene Biologics, ViroThera LLC, Genetix Pharmaceuticals, ImmuneFocus, NanoVax Corp. and OncoShot Biotech. - Vaccine types covered are therapeutic, prophylactic, combined and others. - Cancer types covered are lung cancer, breast cancer, skin cancer, cervical cancer and others. - Applications covered are hospitals and oncology centers, research institutes, homecare settings and others. - Geographic coverage spans North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. - North America coverage includes the United States, Canada and Mexico. - Europe coverage includes Germany, France, the UK, Italy and Russia. - Asia-Pacific coverage includes China, Japan, India, South Korea and Southeast Asia. - Latin America coverage includes Brazil, Argentina and Colombia. - Middle East & Africa coverage includes Saudi Arabia, the UAE, Egypt, Nigeria and South Africa. - The report also reviews market share, competitive positioning, benchmarking, segmented revenue and innovation tracking. - The table of contents includes report overview, trends and competitive landscape, type and end-user segmentation, regional analysis and country-level product commodity analysis.

Between the lines: - The report frames cancer vaccines as a market shaped by both therapeutic and preventive demand, with hospitals, oncology centers and research institutes likely to remain core buyers. - The inclusion of pricing, cost and competitive benchmarking suggests the market is moving from pure growth tracking to execution-focused strategy planning. - The broad geographic scope indicates the opportunity is not limited to one region, but adoption and competition will likely vary by country and care system.

What’s next: - Market participants are likely to use the report to assess segment priorities, regional entry strategies and competitive positioning. - The study says it is designed to help business leaders, investors and industry participants identify growth avenues and optimize market entry. - Coherent Market Insights also offers the report for purchase with a stated discount and provides social links for company updates.**